Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy

Mana Alavi; Raheleh Roudi; Alberto D’Angelo; Navid Sobhani; Fatemeh Safari

doi:10.1007/s11010-025-05219-w

Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy

Mana Alavi
, Raheleh Roudi
, Alberto D’Angelo
, Navid Sobhani
, Fatemeh Safari

Leukemia

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer evades therapy by multiple mechanisms, leading to uncontrolled cell growth and metastasis. Targeted therapies have shown promise in treating cancer by focusing on pathways within cancer cells. The PEAK family, comprising PEAK1 (SgK269), PEAK2 (SgK223/Pragmin), and the latest addition, PEAK3 (C19orf35), plays a crucial role in modulating cellular processes. Dysregulation and hyperactivity of these proteins, through overexpression or mutations, are associated with a wide range of cancers. This review delves into the different roles of the PEAK family members in regulating cell signaling pathways and highlights their potential in cancer therapy.

Original language	English (US)
Pages (from-to)	3521-3533
Number of pages	13
Journal	Molecular and Cellular Biochemistry
Volume	480
Issue number	6
DOIs	https://doi.org/10.1007/s11010-025-05219-w
State	Published - Jun 2025

Keywords

Cancer therapy
Cell signaling pathways
PEAK3
SgK223
SgK269

ASJC Scopus subject areas

Molecular Biology
Clinical Biochemistry
Cell Biology

Access to Document

10.1007/s11010-025-05219-w

Cite this

@article{e7808927117d4df58ae7cf463067bdc3,

title = "Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy",

abstract = "Cancer evades therapy by multiple mechanisms, leading to uncontrolled cell growth and metastasis. Targeted therapies have shown promise in treating cancer by focusing on pathways within cancer cells. The PEAK family, comprising PEAK1 (SgK269), PEAK2 (SgK223/Pragmin), and the latest addition, PEAK3 (C19orf35), plays a crucial role in modulating cellular processes. Dysregulation and hyperactivity of these proteins, through overexpression or mutations, are associated with a wide range of cancers. This review delves into the different roles of the PEAK family members in regulating cell signaling pathways and highlights their potential in cancer therapy.",

keywords = "Cancer therapy, Cell signaling pathways, PEAK3, SgK223, SgK269",

author = "Mana Alavi and Raheleh Roudi and Alberto D{\textquoteright}Angelo and Navid Sobhani and Fatemeh Safari",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.",

year = "2025",

month = jun,

doi = "10.1007/s11010-025-05219-w",

language = "English (US)",

volume = "480",

pages = "3521--3533",

journal = "Molecular and Cellular Biochemistry",

issn = "0300-8177",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy

AU - Alavi, Mana

AU - Roudi, Raheleh

AU - D’Angelo, Alberto

AU - Sobhani, Navid

AU - Safari, Fatemeh

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.

PY - 2025/6

Y1 - 2025/6

N2 - Cancer evades therapy by multiple mechanisms, leading to uncontrolled cell growth and metastasis. Targeted therapies have shown promise in treating cancer by focusing on pathways within cancer cells. The PEAK family, comprising PEAK1 (SgK269), PEAK2 (SgK223/Pragmin), and the latest addition, PEAK3 (C19orf35), plays a crucial role in modulating cellular processes. Dysregulation and hyperactivity of these proteins, through overexpression or mutations, are associated with a wide range of cancers. This review delves into the different roles of the PEAK family members in regulating cell signaling pathways and highlights their potential in cancer therapy.

AB - Cancer evades therapy by multiple mechanisms, leading to uncontrolled cell growth and metastasis. Targeted therapies have shown promise in treating cancer by focusing on pathways within cancer cells. The PEAK family, comprising PEAK1 (SgK269), PEAK2 (SgK223/Pragmin), and the latest addition, PEAK3 (C19orf35), plays a crucial role in modulating cellular processes. Dysregulation and hyperactivity of these proteins, through overexpression or mutations, are associated with a wide range of cancers. This review delves into the different roles of the PEAK family members in regulating cell signaling pathways and highlights their potential in cancer therapy.

KW - Cancer therapy

KW - Cell signaling pathways

KW - PEAK3

KW - SgK223

KW - SgK269

UR - https://www.scopus.com/pages/publications/85218818900

UR - https://www.scopus.com/pages/publications/85218818900#tab=citedBy

U2 - 10.1007/s11010-025-05219-w

DO - 10.1007/s11010-025-05219-w

M3 - Article

C2 - 39922936

AN - SCOPUS:85218818900

SN - 0300-8177

VL - 480

SP - 3521

EP - 3533

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

IS - 6

ER -

Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this